

# Tackling the challenge of *pediatric cancer trials* together with leading oncology institutions



## Innovating for vulnerable communities

Design of clinical trials in the pediatric cancer setting is challenging due to operational and statistical considerations

Working with leading institutions to advance innovative clinical trial designs

# Sanofi *pioneers sustainable finance* in the pharma sector

Committed to integrating sustainability within Play to Win strategy and investment and financing strategy

March 2022

## Sustainability-Linked Bond

The coupon amounts are **linked to the achievement of a sustainability performance target**

The sustainability performance target is:

**Sanofi Global Health to provide essential medicines to 1.5 million patients** by the end of 2026 starting from 2022 (cumulative)



## S&P Global Ratings

“Sanofi has a *strong sustainability focus* on the affordability of medicines, protecting the environment, and promoting the wellbeing of its workforce.”

**ESG profile score**

*80/100*

**Preparedness opinion**  
(score impact)

*Strong (+6)*

ESG  
evaluation

**86**/100

sanofi



ESG  
appendices



Sanofi ESG Q1 *achievements*

## Affordable access



## Global Health Unit #Patients treated

| FY 2021  | Q1 2022  |
|--|--|
| <b>Malaria</b><br>9,276,504<br>23 countries    | <b>Malaria</b><br>1,024,170<br>8 countries <span style="color: green;">●</span>    |
| <b>Tuberculosis</b><br>146,356<br>28 countries | <b>Tuberculosis</b><br>35,094<br>11 countries <span style="color: green;">●</span> |
| <b>NCD</b><br>40,439<br>16 countries           | <b>NCD</b><br>46,300<br>12 countries <span style="color: green;">●</span>          |


## Vials donation

| FY 2021                          | Q1 2022   |
|----------------------------------|---|
| <b>1,083</b><br>patients treated | <b>998</b><br>patients treated <span style="color: green;">●</span> |
| <b>109,677</b><br>vials donated  | <b>22,682</b><br>vials donated <span style="color: green;">●</span> |

## Global access plan

| Q4 2021                 | Q1 2022                              |
|-------------------------|--------------------------------------|
| Pilot phase in progress | <span style="color: green;">=</span> |

## Innovating for vulnerable communities



## Eradicate Polio

| FY 2021   | Q1 2022  |
|---|--|
| <b>50.5million IPV doses</b> supplied to UNICEF | <b>16million IPV doses</b> supplied to UNICEF <span style="color: green;">●</span> |

## Eliminate sleeping sickness

|                                     |                        |
|-------------------------------------|------------------------|
| <b>1.6m</b> patients tested for HAT | KPI updated at Q2 2022 |
| <b>663</b> patients treated         |                        |

## Develop innovative medicines

| FY 2021   | Q1 2022   |
|---|---|
| <b>2</b> assets identified; preclinical studies started | <b>1</b> of the 2 assets <b>in protocol preparation for clinical study</b> <span style="color: green;">●</span> |

Sanofi ESG Q1 *achievements*

## Healthy Planet



## Blister-free vaccines

| Q4 2021                               | Q1 2022  |
|---------------------------------------|--|
| 29% of blister free vaccines produced | Data updated annually <span style="color: green;">=</span> |

## Eco-design

| Q4 2021          | Q1 2022  |
|------------------|--|
| 4 LCAs conducted | 4 LCAs completed & 1 in progress   |
|                  | Eco-design digital solutions project launched <span style="color: green;">●</span> |

## Scope 1 &amp; 2 GHG emissions reduction

| Q4 2021      | Q1 2022   |
|--------------|---|
| -25% vs 2019 | -26% vs 2019 <span style="color: green;">●</span> |

## Renewable electricity &amp; eco-car fleet

| Q4 2021                   | Q1 2022  |
|---------------------------|--|
| 50% renewable electricity | 61% renewable electricity <span style="color: green;">●</span> |
| 26.2% eco-fleet           | 28.7% eco-fleet <span style="color: green;">●</span>           |

## Inclusive workplace



## Diverse Senior Leadership

| Q4 2021  | Q1 2022   |
|--|---|
| 34.2% of our top executives and 40.1% of our executives were women | 35.1% of our top executives and 40.4% of our executives were women <span style="color: green;">●</span> |

## Strengthen social &amp; economic engagement in all communities where we operate

| FY 2021          | Q12022                               |
|------------------|--------------------------------------|
| 4,975 volunteers | Next update in Q2 2022               |
| 26,906 hours     | <span style="color: green;">=</span> |

## From Leaders to Citizens

| Q4 2021                 | Q1 2022                              |
|-------------------------|--------------------------------------|
| Rollout planned in 2022 | <span style="color: green;">=</span> |

# Sanofi ESG ratings

## Rating agencies



| SCORE   |   |  |  |                               |                                  |  |               |  |  |
|---|---|--|--|-------------------------------|----------------------------------|--|---------------|--|--|
| 86/100  | 22<br>Medium risk                       | 86/100   | A  | Climate Change: A<br>Water: A | B                                | 4.2/5  | 3.47/5        | 92%  | 62/100   |
| New rating  | ▲ 22.9                                  | ▲ 84/100   | ▲ B  | ▲ A-                          | = B                              | = 4.2/5  | ▲ 2.49/5      | ▲ 90%  | ▲ 58/100   |
| One of the highest scores across all sectors globally<br>80 points for its solid fundamentals & strong preparedness opinion of 6 points | 11th among 483 pharmaceutical companies | 2 <sup>nd</sup> in ranking among 91 pharmaceutical companies | 4th among the 6 largest pharmaceutical companies | Leading position              | In the Top 3 companies among 391 | With very high rating across the 3 pillars ESG | Top 5 company | Sanofi's disclosure score well above sector disclosure score (74%) | 1st pharmaceutical company out of 57<br>Score in progress since 2018 |

▲ Vs previous rating

Scores assigned by the rating agencies are not equivalent.